Blood markers for lung cancer treatment response
Part of Cancer, Lungs & breathing clinical trials.
This study looks for blood markers that can predict how well certain lung cancer treatments work before surgery. By joining, you help find a simple blood test to guide personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (a common type including adenocarcinoma or squamous cell carcinoma).
- You have not had any prior cancer treatment like chemotherapy, immunotherapy, or radiation for this cancer.
- Your blood counts, liver, and kidney function are within normal ranges (checked by a blood test).
- You are willing to use effective birth control during and for 6 months after the study if needed.
- You do not have cancer that has spread to the brain or other parts of the body beyond the lung.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with stage IIA to IIIB non-small cell lung cancer that can be removed by surgery. It tests if certain white blood cells (neutrophils) can help predict how well chemotherapy combined with immunotherapy works before surgery.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial tests whether certain markers in your blood or tissue can predict how well immunotherapy works before surgery for early-stage lung cancer. It aims to find out who benefits most from this treatment.
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.